A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled

NCT02526875 Phase 4 UNKNOWN

To Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine (Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy

Details

Lead sponsor	Chong Kun Dang Pharmaceutical
Phase	Phase 4
Status	UNKNOWN
Enrolment	208
Start date	2015-04
Completion	2017-11

Conditions

• Hypertension

Interventions

• Telminuvo®Tab. 40/2.5mg

Primary outcomes

• Change from baseline in the 24hr mean blood pressure by ambulatory blood pressure monitoring(ABPM) at week 8. — Baseline and week 8
  Change from baseline in the 24hr mean blood pressure by ambulatory blood pressure monitoring(ABPM) at week 8.

Countries

South Korea